Advaxis (OTCMKTS:ADXS – Get Rating) and Atea Pharmaceuticals (NASDAQ:AVIR – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.
Profitability
This table compares Advaxis and Atea Pharmaceuticals' net margins, return on equity and return on assets.
Get Advaxis alerts:| Net Margins | Return on Equity | Return on Assets | |
| Advaxis | N/A | -42.66% | -36.09% |
| Atea Pharmaceuticals | 34.49% | 2.36% | 2.05% |
Institutional and Insider Ownership
6.7% of Advaxis shares are owned by institutional investors. Comparatively, 64.4% of Atea Pharmaceuticals shares are owned by institutional investors. 0.3% of Advaxis shares are owned by company insiders. Comparatively, 12.8% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Advaxis and Atea Pharmaceuticals' revenue, earnings per share (EPS) and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Advaxis | $3.24 million | 2.23 | -$17.86 million | ($0.10) | -39.80 |
| Atea Pharmaceuticals | $351.37 million | 1.86 | $121.19 million | $0.11 | 71.18 |
Atea Pharmaceuticals has higher revenue and earnings than Advaxis. Advaxis is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current recommendations and price targets for Advaxis and Atea Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Advaxis | 0 | 0 | 0 | 0 | N/A |
| Atea Pharmaceuticals | 1 | 2 | 0 | 0 | 1.67 |
Atea Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 2.17%. Given Atea Pharmaceuticals' higher probable upside, analysts plainly believe Atea Pharmaceuticals is more favorable than Advaxis.
Risk & Volatility
Advaxis has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500.
Summary
Atea Pharmaceuticals beats Advaxis on 10 of the 12 factors compared between the two stocks.
About Advaxis
(Get Rating)
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
About Atea Pharmaceuticals
(Get Rating)
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.